This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Heart Failure Hypertension Preserved Ejection Fraction 
DAIC
MAY 6, 2024
Initially discovered and developed by Orion Corporation in Finland, intravenous levosimendan is approved in 60 countries outside the United States for use in hospitalized patients with acutely decompensated heart failure. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,
Heart BMJ
MARCH 26, 2025
Heart failure (HF) is one of the significant complications in patients with myocardial infarction (MI), leading to increased risk for cardiovascular morbidity and mortality. Common predictors include older age, prior hypertension, diabetes and atrial fibrillation. HFrEF is more commonly.
Journal of Clinical Investigation - Cardiology
DECEMBER 15, 2023
Heart failure with preserved ejection fraction (HFpEF) is a widespread syndrome with limited therapeutic options and poorly understood immune pathophysiology.
Frontiers in Cardiovascular Medicine
NOVEMBER 17, 2024
BackgroundAnemia is a common complication in patients with heart failure and is associated with left ventricular systolic dysfunction.
DAIC
JUNE 4, 2024
American College of Cardiology (ACC) and American Heart Association (AHA) Issue New Hypertrophic Cardiomyopathy (HCM) Management Guidelines 2. New Study Published in JACC: Heart Failure Reveals that Despite Significant Efforts to Improve Acute Heart Failure Treatment Over the Past 20 Years, Management Remains Unchanged 3.
European Journal of Heart Failure
APRIL 13, 2025
The beneficial effects of finerenone in patients with heart failure (HF) and mildly reduced or preserved ejection fraction were consistent, regardless of a history of chronic obstructive pulmonary disease (COPD) status.
HeartRhythm
SEPTEMBER 4, 2024
Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) are comorbid conditions that are increasingly prevalent and have a high socioeconomic burden. This article discusses their shared pathophysiology, focusing on the triad of hypertension, obesity, and aging.We
Circulation: Heart Failure
JANUARY 28, 2025
Circulation: Heart Failure, Ahead of Print. BACKGROUND:The therapeutic armamentarium for heart failure with preserved ejection fraction (HFpEF) remains notably constrained. compared with single condition exposure 5.21.3% (obesity), 6.73.5% (hypertension), and 9.01.1% (diabetes;P<0.001).
Journal of the American Heart Association
DECEMBER 29, 2023
Journal of the American Heart Association, Ahead of Print. BackgroundPulmonary hypertension (PH) is highly prevalent in patients with heart failure with preserved ejection fraction (HFpEF), and it is a strong predictor of adverse outcomes.
European Journal of Heart Failure
DECEMBER 7, 2023
Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF). Obesity was associated with more first and recurrent heart failure events.
Heart BMJ
FEBRUARY 23, 2024
Objective The heterogeneous pathophysiology of the diverse heart failure with preserved ejection fraction (HFpEF) phenotypes needs to be examined. We aim to assess differences in the biomarkers among the phenotypes of HFpEF and investigate its multifactorial pathophysiology.
Hypertension Journal
FEBRUARY 22, 2024
Hypertension, Ahead of Print. Background:We tested the hypothesis that patients with heart failure with preserved ejection fraction (HFpEF) would have greater muscle sympathetic nerve activity (MSNA) at rest and sympathetic reactivity during a cold pressor test compared with non–heart failure controls.
European Journal of Heart Failure
NOVEMBER 19, 2024
Hypertensive disorders of pregnancy as a risk factor for heart failure. Hypertensive disorders of pregnancy (HDP) occur in almost 10% of gestations and preeclampsia, a more severe form, in 34%.
40 
American College of Cardiology
JULY 11, 2024
What is the safety and efficacy of tadalafil in patients with heart failure with preserved ejection fraction (HFpEF) and combined postcapillary and precapillary pulmonary hypertension (CpcPH)?
Circulation
MARCH 16, 2025
Circulation, Volume 151, Issue 11 , Page e763-e763, March 18, 2025.
Circulation
MARCH 9, 2025
Circulation, Volume 151, Issue 10 , Page e686-e686, March 11, 2025.
DAIC
JANUARY 23, 2024
Getty Images milla1cf Tue, 01/23/2024 - 13:38 January 23, 2024 — Sequana Medical NV , a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announced that an independent Data and Safety Monitoring Board (DSMB) approved the start of the randomized cohort in MOJAVE , the US Phase 1/2a study of DSR 2.0
104 
Journal of the American Heart Association
DECEMBER 29, 2023
Journal of the American Heart Association, Ahead of Print.
HeartRhythm
APRIL 30, 2024
Introduction: Patients with ‘heart failure with preserved ejection fraction’ (HFpEF) frequently manifest chronotropic incompetence as well as hypertension (HTN). Cardiac pacing may improve clinical outcomes in these patients. To date, pacing has not been regulated by an external hemodynamic input.
Dr. S. Venkatesan MD
AUGUST 3, 2024
However, It is surprising even in chronic pulmonary hypertension , the degree of RVH is not constant and homogenous.This is because , different parts of RV chamber has different wall thickness.Further, the pressure distribution from PA to RV is uneven. Eur J Heart Fail. Eur J Heart Fail 2016; 18: 226 2018 Jan;20(1):16-37.
Circulation
NOVEMBER 11, 2024
Intro:Drug Development for Heart failure with Preserved Ejection Fraction (HFpEF) is a major challenge facing cardiovascular research due to its complex pathophysiology and existence of comorbidities, leading to recognize distinct HFpEF phenogroups. l) for 8 weeks.
Circulation
APRIL 1, 2025
BACKGROUND:Heart failure with preserved ejection fraction (HFpEF) has become the most prevalent type of heart failure, but effective treatments are lacking. Cardiac lymphatics play a crucial role in maintaining heart health by draining fluids and immune cells. Circulation, Ahead of Print.
Circulation
NOVEMBER 11, 2024
The CardioMEMS PA (pulmonary artery) sensor allows remote pulmonary artery diastolic (PAD) pressure monitoring to adjust diuresis in heart failure with preserved ejection fraction (HFpEF).
Dr. S. Venkatesan MD
APRIL 18, 2024
Shah, author of Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: The REDUCE LAP-HF II Randomized Clinical Trial. Here is an audio podcast from the primary author published in JAMA network. Interview with Sanjiv J. Hosted by James E.
DAIC
FEBRUARY 29, 2024
ET Main Tent (Hall B1) Effect of Gamification, Financial Incentives or Both Combined to Increase Physical Activity Among Patients with Elevated Risk For Major Adverse Cardiovascular Events.
103 Circulation
NOVEMBER 11, 2024
Introduction:Heart failure with preserved ejection fraction (HFpEF) is a form of heart failure which is rapidly rising in incidence in the US today. g/L of an iNOS inhibitor (N-Nitro-L-arginine methylester) to induce hypertension.
DAIC
MARCH 26, 2025
Food and Drug Administration (FDA) accepted its supplemental new drug application (sNDA) and granted Priority Review designation for KERENDIA(finerenone) for the treatment of adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).
European Journal of Heart Failure
APRIL 6, 2025
Abstract Aims Oxidative stress is known to be involved in the pathophysiology of heart failure (HF). During a median follow-up of 12.6years, 349 (4.3%) HF events occurred of which 118 (33.8%) had HF with preserved ejection fraction.
Circulation
OCTOBER 13, 2023
BACKGROUND:Apparent treatment-resistant hypertension (aTRH) is prevalent and associated with adverse outcomes in heart failure with mildly reduced or preserved ejection fraction. Nonresistant hypertension was defined as BP above threshold but not meeting aTRH criteria. per 100 patient-years).
European Journal of Heart Failure
FEBRUARY 5, 2025
Beta-blockers are commonly used in patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Methods and results We pooled individual patient data from four large HFmrEF/HFpEF trials (I-Preserve, TOPCAT, PARAGON-HF, and DELIVER).
European Journal of Heart Failure
FEBRUARY 4, 2024
Abstract Aim Pathophysiological differences between patients with heart failure with preserved (HFpEF) and reduced (HFrEF) ejection fraction (EF) remain unclear. Study design and main study results. In HFrEF, interleukin (IL)-8 and IL-6 were possible targets related to lower EF and worsening renal function.
Frontiers in Cardiovascular Medicine
AUGUST 6, 2024
Hypertension during pregnancy affects up to 10% of pregnancies and is associated with significant cardiovascular morbidity and mortality. Finally, we explore how future cardiovascular risk may be predicted based on cardiac remodelling during or after pregnancy and suggest potential areas of further research in the field.
DAIC
MARCH 29, 2024
About Heart Failure Heart failure (HF) is a chronic, progressive disease in which the heart cannot pump enough blood to meet the body's needs. HFpEF is HF with preserved ejection fraction in which pressure builds up in the heart and lungs due to a stiffened left ventricle.
Journal of the American Heart Association
JANUARY 23, 2025
Journal of the American Heart Association, Ahead of Print. BackgroundCardiometabolic comorbidities such as obesity, diabetes, and hypertension are highly prevalent in heart failure (HF). Severely uncontrolled comorbidities were defined as systolic blood pressure 160 mm Hg, hemoglobin A1c 8%, and body mass index 35 kg/m2.
DAIC
JUNE 26, 2024
Getty Images milla1cf Wed, 06/26/2024 - 18:59 June 26, 2024 — Semaglutide , a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options.
Circulation
NOVEMBER 11, 2024
Introduction:The demographics of patients with pulmonary arterial hypertension (PAH) is shifting towards older age, increased comorbidity burden, and an increase in the risk of left ventricular (LV) diastolic dysfunction. 2022 were included. 2022 were included.
40 
Open Heart
FEBRUARY 15, 2023
AFMR is likely to become more common with population ageing, alongside increases in atrial fibrillation and heart failure with preserved ejection fraction; conditions causing atrial dilatation. Advancing age and pulmonary hypertension independently associated with survival in FMR.
Cardiometabolic Health Congress
JULY 25, 2023
There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] Is the obesity paradox a real phenomenon?
52 
Journal of the American Heart Association
MARCH 13, 2025
Journal of the American Heart Association, Ahead of Print. BackgroundSparce data suggest higher mortality in heart failure (HF) with left ventricular ejection fraction (EF) >65% to 70%. We characterized EF distribution, characteristics, and outcomes in patients with HF and EF 50%.Methods
Frontiers in Cardiovascular Medicine
DECEMBER 16, 2024
ObjectiveThe left atrial stiffness index (LASI) holds significance in the atrioventricular coupling function and heart failure progression. To assess left atrial function and evaluate the relationship between LASI and exercise capacity in hypertension-related heart failure with preserved ejection fraction (HT-HFpEF).MethodsThe
Cardiometabolic Health Congress
NOVEMBER 22, 2024
Heart Failure Management : The FINEARTS-HF trial focused on the efficacy of finerenone, an aldosterone antagonist, in reducing heart failure hospitalizations and cardiovascular mortality among patients with preserved ejection fraction (HFpEF).
The British Journal of Cardiology
JANUARY 14, 2025
We report from the 19 th Annual Scientific Meeting of the Cardiorenal Forum held in London on 4 th October 2024, which served as a dynamic platform for experts in cardiology, diabetes, and renal medicine to converge and exchange the latest insights on managing heart and kidney failure.
40 
Cardiometabolic Health Congress
NOVEMBER 14, 2024
42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. Additionally, 10% of the global population suffers from chronic kidney disease , with diabetes and hypertension as significant risk factors. In the U.S.,
103 
Open Heart
DECEMBER 3, 2024
Aims Pulmonary hypertension (PHT) appears to be very common in heart failure with preserved ejection fraction but details on its prevalence, severity and prognostic implications have not been well defined.
52
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content